Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Alisertib, Bortezomib e Rituximab nel trattamento di pazienti con linfoma mantellare recidivante o refrattario o linfoma non-Hodgkin a basso grado a cellule B

17 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio di fase I su MLN8237 in combinazione con bortezomib e rituximab nel linfoma mantellare recidivato e refrattario e non-Hodgkin di basso grado

This phase I trial studies the side effects and best dose of alisertib and bortezomib when given together with rituximab in treating patients with mantle cell lymphoma or B-cell low grade non-Hodgkin lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Alisertib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving alisertib and bortezomib together with rituximab may be a better treatment for relapsed or refractory mantle cell lymphoma or B-cell low grade non-Hodgkin lymphoma.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose of alisertib (MLN8237) and bortezomib when combined with rituximab in patients with relapsed/refractory mantle cell and B-cell low grade non-Hodgkin lymphoma.

SECONDARY OBJECTIVES:

I. To describe the rate of overall response (complete response and partial response) for patients with relapsed/refractory mantle cell and B-cell low grade non-Hodgkin lymphoma treated with the combination of MLN8237 plus bortezomib and rituximab.

TRANSLATIONAL OBJECTIVES:

I. To evaluate the clinical significance of Aurora A over-expression and the proliferative index in initial tumor biopsy specimens from patients with relapsed/refractory mantle cell and B-cell low grade non-Hodgkin lymphoma treated with the combination of MLN8237 plus bortezomib and rituximab.

II. To evaluate and compare in paired biopsy specimens pre-treatment and on day 8: apoptosis and G2M arrest, and the expression level of cell cycle related proteins including: cyclin D1, p53, BIM-1, p27, p21, noxa, puma and survivin.

OUTLINE: This is a dose-escalation study of alisertib and bortezomib.

Patients receive alisertib orally (PO) twice daily (BID) on days 1-7; bortezomib subcutaneously (SC) on days 1, 8, and 15; and rituximab intravenously (IV) on day 1. Treatment repeats every 28 days* in the absence of disease progression or unacceptable toxicity.

Note: *After 8 courses, treatment with rituximab repeats once every 3 courses (12 weeks) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

24

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New York
      • New York, New York, Stati Uniti, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • The Bronx, New York, Stati Uniti, 10461
        • Montefiore Medical Center-Einstein Campus
      • The Bronx, New York, Stati Uniti, 10467
        • Montefiore Medical Center - Moses Campus
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19111
        • Fox Chase Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients must have histologically confirmed relapsed or refractory mantle cell lymphoma or low grade B-cell non-Hodgkin lymphoma (NHL); patients with evidence of transformation to a high grade histology will not be eligible
  • Measurable or evaluable disease, as defined in 2008 Revised Response Criteria for Malignant Lymphoma; baseline scans used for measurement should be obtained within 30 days of registration, and baseline bone marrow biopsy and/or aspiration should be obtained with 90 days of registration
  • Patients may have received one or more lines of prior chemotherapy with/without rituximab (including high dose therapy plus stem cell transplant which is counted as one regimen); prior bortezomib is allowed; patients must not have received bortezomib in the past 6 months
  • Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ CD4+ cells/mm^3, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions
  • Patients must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 (Karnofsky >= 60%)
  • Leukocytes >= 3,000/mcL (obtained within 30 days of registration)
  • Absolute neutrophil count >= 1,500/mcL (obtained within 30 days of registration)
  • Platelets >= 75,000/mcL or >= 50,000/mcL with documented bone marrow involvement (obtained within 30 days of registration)
  • Total bilirubin within normal institutional limits (may be elevated if direct bilirubin normal) (obtained within 30 days of registration)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 3 X institutional upper limit of normal (obtained within 30 days of registration)
  • Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal (obtained within 30 days of registration)
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of MLN8237 administration
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C, 3 weeks for rituximab) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier

  • Patients who are receiving any other investigational agents

  • Patients with known brain metastases should be excluded from this clinical trial

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, bortezomib or rituximab

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Known history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen, or any conditions that could result in excessive toxicity associated with the benzodiazepine-like effects of MLN8237

  • Inability to swallow oral medication or to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration or any condition that would modify small bowel absorption of oral medications, including malabsorption, or resection of pancreas or upper bowel

  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237

  • HIV-positive patients on combination antiretroviral therapy which include cytochrome p450 inhibitors are ineligible; patients with CD4 counts less than 300 CD4+ cells/mm^3 and or a high viral load are ineligible

  • Grade 2 or greater neuropathy

  • The following agents are not permitted while patients are taking MLN8237, and should be discontinued at prior to registration if patients are taking them:

    • Patients must stop using the proton pump inhibitor (PPI) for at least 4 days prior to the first dose of MLN8237; administration of PPI while on study is not permitted
    • Histamine-2 (H2) receptor antagonists are not permitted from the day prior through to the end of MLN8237 dosing, except as required for premedication for rituximab; constant dosing of H2 blockers is not permitted
    • Antacid preparations are not permitted for 2 hours before or 2 hours after administration of MLN8237
    • Administration of pancreatic enzymes is not permitted at any time while on study
    • Co-administration of enzyme-inducing antiepileptic drugs, rifampin, rifabutin, rifapentine or St. John's wort is not permitted
    • Concurrent bisphosphonate therapy is allowed if it was started before study entry and is maintained at recommended dosing intervals; if bisphosphonate therapy is initiated after study entry, bone lesions will not be considered evaluable for disease response
    • Patients must be willing not drive, operate dangerous tools or machinery, or engage in any other potentially hazardous activity that requires full alertness and coordination if they experience excessive sedation; if a patient experiences excessive sedation believed to be related to MLN8237, treatment with MLN8237 should be interrupted
    • Patients must be willing to limit alcohol consumption to no more than 1 standard unit of alcohol (12 oz beer [350 mL], 1.5 oz [45 mL] of 80-proof alcohol, or one 6-oz [175 mL] glass of wine) per day during the study and for 30 days from the last dose of MLN8237; minimize the use of agents with central nervous system (CNS) effects
    • Benzodiazepine use is discouraged but not prohibited

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (alisertib, bortezomib, and rituximab)

Patients receive alisertib PO BID on days 1-7; bortezomib SC on days 1, 8, and 15; and rituximab IV on day 1. Treatment repeats every 28 days* in the absence of disease progression or unacceptable toxicity.

Note: *After 8 courses, treatment with rituximab repeats once every 3 courses (12 weeks) in the absence of disease progression or unacceptable toxicity.

Correlative studies

Given IV

Altri nomi:
  • Rituxan
  • MabThera
  • PAB 798
  • BI 695500
  • Anticorpo monoclonale C2B8
  • Anticorpo chimerico anti-CD20
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • Anticorpo monoclonale IDEC-C2B8
  • PF-05280586
  • Riabni
  • Rituximab ABBS
  • Rituximab ARX
  • Rituximab biosimilare ABP 798
  • Rituximab Biosimilare BI 695500
  • Rituximab Biosimilare CT-P10
  • Rituximab biosimilare GB241
  • Rituximab biosimilare IBI301
  • Rituximab biosimilare JHL1101
  • Rituximab biosimilare PF-05280586
  • Rituximab biosimilare RTXM83
  • Rituximab biosimilare SAIT101
  • Rituximab biosimilare SIBP-02
  • rituximab biosimilare TQB2303
  • Rituximab PVVR
  • Rituximab-arrx
  • Rituximab-pvvr
  • RTXM83
  • Ruxienza
  • Truxima
  • Rixathon
  • Ikgdar
  • Mabtas
  • Rituximab-abbs
  • BI-695500
  • BI695500
  • Blittima
  • IDEC102
  • PF05280586
  • Ritemvia
  • Rituximab-blit
  • Rito Rituximab
  • Rituximab-rixa
  • Rituximab-rixi
  • Riximyo
  • RTXM-83
  • ABP-798
  • ABP798
  • CT P10
  • CTP10
  • GP2013
  • GP-2013
  • Rituximab biosimilare GP2013

Given PO

Altri nomi:
  • MLN8237
  • Inibitore della chinasi Aurora A MLN8237
  • MLN-8237
  • MLN 8237

Given SC

Altri nomi:
  • Velcade
  • MLN341
  • PS-341
  • LDP 341
  • Acido [(1R)-3-metil-1-[[(2S)-1-osso-3-fenil-2-[(pirazinilcarbonil)ammino]propil]ammino]butil]boronico
  • PS341
  • LDP-341
  • MLN-341
  • LDP341
  • 341 mln
  • PS 341
  • Boruzu

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Recommended phase II dose of alisertib when combined with bortezomib and rituximab, defined as the highest dose level at which < 33% of the dose cohort experience a dose limiting toxicity (DLT)
Lasso di tempo: 21 days

Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Toxicities will be described by intensity at each dose level.

21 days
Recommended phase II dose of bortezomib when combined with alisertib and rituximab, defined as the highest dose level at which < 33% of the dose cohort experience a dose limiting toxicity (DLT)
Lasso di tempo: 21 days

Graded using the NCI CTCAE version 5.0. Toxicities will be described by intensity at each dose level.

21 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Sopravvivenza globale
Lasso di tempo: Dal momento della randomizzazione alla data del decesso per qualsiasi causa, valutato fino a 30 giorni dopo il trattamento
Dal momento della randomizzazione alla data del decesso per qualsiasi causa, valutato fino a 30 giorni dopo il trattamento
Overall response rate (ORR) (complete response and partial response)
Lasso di tempo: Up to 30 days post-treatment

ORR will be summarized descriptively.

Up to 30 days post-treatment
Progression free survival (PFS)
Lasso di tempo: From time of study entry to the first documentation of tumor progression or death due to any cause, whichever comes first, assessed up to 30 days post-treatment

Kaplan-Meier methodology will be used to summarize estimate median PFS for patients in all treatment groups.

From time of study entry to the first documentation of tumor progression or death due to any cause, whichever comes first, assessed up to 30 days post-treatment
Duration of response (DOR)
Lasso di tempo: From time of documentation of a response to treatment to the first documentation of documentation of tumor progression or death due to any cause whichever comes first, assessed up to 30 days post-treatment

Kaplan-Meier methodology will be used to summarize estimate median DOR for patients in all treatment groups.

From time of documentation of a response to treatment to the first documentation of documentation of tumor progression or death due to any cause whichever comes first, assessed up to 30 days post-treatment

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Aurora A expression measured from patient biopsy specimens
Lasso di tempo: Up to day 8 (course 1)

Statistical techniques such as T-tests for bivariate analyses and logistic regression modeling for multivariable analyses will be applied to assess the association between initial Aurora A expression measured from patient biopsy specimens with response to therapy and other clinical outcomes. In patients who consent to biopsy, findings will be reported descriptively since these analyses will be viewed as exploratory in nature.

Up to day 8 (course 1)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Catherine S Diefenbach, Montefiore Medical Center - Moses Campus

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

31 agosto 2012

Completamento primario (Effettivo)

29 maggio 2018

Completamento dello studio (Stimato)

3 marzo 2027

Date di iscrizione allo studio

Primo inviato

26 settembre 2012

Primo inviato che soddisfa i criteri di controllo qualità

26 settembre 2012

Primo Inserito (Stimato)

28 settembre 2012

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NCI-2012-01712
  • P30CA013330 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI-2012-01712 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • S12-02028
  • CDR0000740877
  • P9086
  • 9086 (Altro identificatore: CTEP)
  • 9086 (Altro identificatore: Montefiore Medical Center - Moses Campus)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .